- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:06 | Earnings call: Novozymes maintains steady outlook amid modest growth | 2 | Investing.com | ||
| Fr | Novozymes A/S: Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration | 279 | GlobeNewswire (Europe) | For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA... ► Artikel lesen | |
| Fr | Novozymes A/S: Trading statement Q1 2024 | 83 | GlobeNewswire (Europe) | Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: "I am pleased with the first quarter organic sales growth of 4% with... ► Artikel lesen | |
| Mi | Dividendenbekanntmachungen (01.05.2024) | 3.772 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BALOISE HOLDING AG ADR US0587791098 0,4983 USD 0,467 EUR CANADIAN UTILITIES LIMITED CA1367178326 0,453 CAD 0,3082 EUR DANONE SA... ► Artikel lesen | |
| Di | Novozymes A/S: Resolutions from the annual shareholders' meeting 2024 | 178 | GlobeNewswire (Europe) | Today an ordinary shareholders' meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an... ► Artikel lesen | |
| 08.04. | Novozymes A/S: Invitation to the annual shareholders' meeting | 476 | GlobeNewswire (USA) | ||
| 08.04. | Novozymes A/S: Share-based legacy RSU program granted | 292 | GlobeNewswire (USA) | ||
| 27.03. | NASDAQ OMX Nordic: Change of name and ticker code for Novozymes (97/24) | 263 | GlobeNewswire | The Extraordinary General Meeting (EGM) of Novozymes A/S (Novozymes) held on
March 4, 2024 approved a secondary name of the company Novonesis A/S. As a
consequence of the name change, Novozymes has... ► Artikel lesen | |
| 22.03. | Novonesis showcased mood support probiotic at Expo West: MindAble 1714 targets gut-brain axis | 16 | Food Business News | ||
| 21.03. | Novozymes A/S: 2024 outlook and pro forma financials | 50 | GlobeNewswire (USA) | ||
| 18.03. | Novozymes A/S: Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 | 16 | GlobeNewswire (USA) | ||
| 18.03. | Biotalys NV: Biotalys and Novonesis announce manufacturing and commercialisation partnership for EVOCA NG | 466 | GlobeNewswire (Europe) | Press release - inside information
Biotalys and Novonesis have entered into an agreement to advance EVOCA NG - the next generation of Biotalys' product candidate EVOCA* - to the final stage of development.Pending... ► Artikel lesen | |
| 12.03. | FMC Canada to distribute Novonesis biosolutions in 2025 | 20 | Investing.com | ||
| 08.03. | NASDAQ OMX Nordic: Anticipated change of name and ticker code for Novozymes (67/24) | 434 | GlobeNewswire | The Extraordinary General Meeting (EGM) of Novozymes A/S (Novozymes) held on
March 4, 2024, approved a secondary name of the company Novonesis A/S. As a
consequence, Novozymes has changed its stock... ► Artikel lesen | |
| 05.03. | Nasdaq Copenhagen A/S: Novozymes A/S - change of share name to Novonesis (Novozymes)B | 335 | GlobeNewswire | The changes below will take effect on Nasdaq Copenhagen as per 6 March 2024.
ISIN: DK0060336014
------------------------------------------------
Name Novozymes B ... ► Artikel lesen | |
| 04.03. | Novozymes A/S: Resolutions from the Extraordinary Shareholders' Meeting 2024 | 294 | GlobeNewswire (Europe) | Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders' meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and amendment... ► Artikel lesen | |
| 09.02. | Invitation to an extraordinary shareholders' meeting of Novozymes A/S | 30 | GlobeNewswire (USA) | ||
| 02.02. | Novonesis emerges from Chr. Hansen-Novozymes merger: The new company offers enzymes, microbial technologies and ingredients | 43 | Food Business News | ||
| 02.02. | Novozymes A/S: Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed | 392 | GlobeNewswire (Europe) | Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of all... ► Artikel lesen | |
| 01.02. | Recap: Novozymes Q4 Earnings | 32 | Benzinga.com |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec, HelloFresh, K+S, Lanxess, Rheinmetall, SMA Solar und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
Das Unternehmen NOVONESIS A/S ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,98 % bei einem Aktienkurs von 51,50 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,17 Euro errechnet sich eine Dividendendrendite von +0,34 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
